论文部分内容阅读
目的分析双表型急性白血病的免疫学特征,临床疗效及预后。方法根据EGIL标准诊断双表型急性白血病采用流式细胞仪分析急性白血病的免疫表型。结果双表型急性白血病的构成比为8.9%,CD34表达阳性率为75%,P170表达阳性率为70%,明显高于同期非双表型急性白血病(P<0.05;P<0.05);12例患者治疗后完全缓解率为33.3%,12个月总生存率为8.3%,明显低于同期非双表型急性白血病(P<0.05;P<0.01);疗效与CD34和P170表达呈负相关。结论双表型急性白血病常伴有较多的不良预后因素,治疗效果差,生存期短。
Objective To analyze the immunological characteristics, clinical efficacy and prognosis of biphenotypic acute leukemia. Methods According to the diagnostic criteria of EGIL, the immunophenotype of acute leukemia was analyzed by flow cytometry in patients with dual phenotype acute leukemia. Results The positive rate of CD34 expression in CDDP was 8.9%, the positive rate of CD34 expression was 70%, and the positive rate of P170 expression was significantly higher than that of non-dual phenotype acute leukemia (P <0.05; P <0.05) .12 The complete remission rate of patients after treatment was 33.3%, and the 12-month overall survival rate was 8.3%, which was significantly lower than that of non-dual-phenotype acute leukemia (P <0.05; P <0.01). The curative effect was negatively correlated with the expression of CD34 and P170 . Conclusions Dual-phenotype acute leukemia often accompanied by more adverse prognostic factors, the treatment effect is poor, short survival.